Jennifer A. Dickens

Jennifer A. Dickens

Auto-generated profile, based on publicly available information

Jennifer A. Dickens

Interstitial Lung Disease Service, Royal Papworth Hospital, Cambridge, UK

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2011 in Respiratory Research
Verified
Journal Article
Open access
PDF file
JDJennifer A Dickens
Jennifer A Dickens
BMBruce E Miller
Bruce E Miller
LELisa D Edwards
Lisa D Edwards
ESEdwin K Silverman
Edwin K Silverman
DLDavid A Lomas
David A Lomas
TIthe Evaluation of COPD Longitudinally to Identify Surrogate Endpoints (ECLIPSE) study investigators
the Evaluation of COPD Longitudinally to Identify Surrogate Endpoints (ECLIPSE) study investigators
Background: There is a need for biomarkers to better characterise individuals with COPD and to aid with the development of therapeutic interventions. A panel of putative blood biomarkers was assessed in a subgroup of the Evaluation of COPD Longitudinally to Identify Surrogate Endpoints (ECLIPSE) cohort. Methods: Thirty-four blood biomarkers were assessed in 201 subjects with COPD, 37 ex-smoker controls with normal lung function and 37 healthy non-smokers selected from the ECLIPSE cohort. Biomarker repeatability was assessed using baseline and 3-month samples. Intergroup comparisons were made using analysis of variance, repeatability was assessed through Bland-Altman plots, and correlations between biomarkers and clinical characteristics were assessed using Spearman correlation coefficients. Results: Fifteen biomarkers were significantly different in individuals with COPD when compared to former or non-smoker controls. Some biomarkers, including tumor necrosis factor-α and interferon-γ, were measurable in only a minority of subjects whilst others such as C-reactive protein showed wide variability over the 3-month replication period. Fibrinogen was the most repeatable biomarker and exhibited a weak correlation with 6-minute walk distance, exacerbation rate, BODE index and MRC dyspnoea score in COPD subjects. 33% (66/201) of the COPD subjects reported at least 1 exacerbation over the 3 month study with 18% (36/201) reporting the exacerbation within 30 days of the 3-month visit. CRP, fibrinogen interleukin-6 and surfactant protein-D were significantly elevated in those COPD subjects with exacerbations within 30 days of the 3-month visit compared with those individuals that did not exacerbate or whose exacerbations had resolved. Conclusions: Only a few of the biomarkers assessed may be useful in diagnosis or management of COPD where the diagnosis is based on airflow obstruction (GOLD). Further analysis of more promising biomarkers may reveal utility in subsets of patients. Fibrinogen in particular has emerged as a potentially useful biomarker from this cohort and requires further investigation. Trial Registration: SCO104960, clinicaltrials.gov identifier NCT00292552

15 January 2025 in The EMBO Journal
Verified
Journal Article
Open access
KLKyungtae Lim
Kyungtae Lim
EREimear N Rutherford
Eimear N Rutherford
LDLivia Delpiano
Livia Delpiano
PHPeng He
Peng He
WLWeimin Lin
Weimin Lin
JDJennifer A Dickens
Jennifer A Dickens
Alveolar type 2 (AT2) cells maintain lung health by acting as stem cells and producing pulmonary surfactant. AT2 dysfunction underlies many lung diseases, including interstitial lung disease (ILD), in which some inherited forms result from the mislocalization of surfactant protein C (SFTPC) variants. Lung disease modeling and dissection of the underlying mechanisms remain challenging due to complexities in deriving and maintaining human AT2 cells ex vivo. Here, we describe the development of mature, expandable AT2 organoids derived from human fetal lungs which are phenotypically stable, can differentiate into AT1-like cells, and are genetically manipulable. We use these organoids to test key effectors of SFTPC maturation identified in a forward genetic screen including the E3 ligase ITCH, demonstrating that their depletion phenocopies the pathological SFTPC redistribution seen for the SFTPC-I73T variant. In summary, we demonstrate the development of a novel alveolar organoid model and use it to identify effectors of SFTPC maturation necessary for AT2 health.

28 May 2021 in European Respiratory Journal
Verified
Journal Article
Open access
PDF file
JDJennifer A. Dickens
Jennifer A. Dickens
EREimear N. Rutherford
Eimear N. Rutherford
SASusana Abreu
Susana Abreu
JCJoseph E. Chambers
Joseph E. Chambers
MEMatthew O. Ellis
Matthew O. Ellis
SMStefan J. Marciniak
Stefan J. Marciniak
Background: Alveolar epithelial cell dysfunction plays an important role in the pathogenesis of idiopathic pulmonary fibrosis (IPF), but remains incompletely understood. Some monogenic forms of pulmonary fibrosis are associated with expression of mutant surfactant protein C (SFTPC). The commonest pathogenic mutant, I73T, mislocalises to the alveolar epithelial cell plasma membrane and displays a toxic gain of function. Because the mechanisms explaining the link between this mutant and IPF are incompletely understood, we sought to interrogate SFTPC trafficking in health and disease to understand the functional significance of SFTPC-I73T relocalisation.Methods: We performed mechanistic analysis of SFTPC trafficking in a cell model that reproduces thein vivophenotype and validated findings in human primary alveolar organoids.Results: We show that wild-type SFTPC takes an unexpected indirect trafficking routeviathe plasma membrane and undergoes the first of multiple cleavage events before reaching the multivesicular body (MVB) for further processing. SFTPC-I73T takes this same route, but its progress is retarded both at the cell surface and due to failure of trafficking into the MVB. Unable to undergo onward trafficking, it is recycled to the plasma membrane as a partially cleaved intermediate.Conclusion: These data show for the first time that all SFTPC transits the cell surface during normal trafficking, and the I73T mutation accumulates at the cell surface through both retarded trafficking and active recycling. This understanding of normal SFTPC trafficking and how the I73T mutant disturbs it provides novel insight into SFTPC biology in health and disease, and in the contribution of the SFTPC mutant to IPF development.

27 May 2025 in Thorax
Verified
Journal Article
Open access
PDF file
RHRichard J Hewitt
Richard J Hewitt
LPLaurence Pearmain
Laurence Pearmain
ELElisavet Lyka
Elisavet Lyka
JDJennifer Dickens
Jennifer Dickens
Background Idiopathic pulmonary fibrosis (IPF) is a progressive disease of lung parenchymal scarring that is triggered by repeated microinjury to a vulnerable alveolar epithelium. It is increasingly recognised that cellular ageing, whether physiological or accelerated due to telomere dysfunction, renders the epithelium less able to cope with injury and triggers changes in epithelial behaviour that ultimately lead to the development of disease. Aims This review aims to highlight how, with increasing age, the alveolar epithelium becomes vulnerable to exogenous insults. We discuss the downstream consequences of alveolar epithelial dysfunction on epithelial phenotype, alveolar repair and pro-pathogenic interactions with other alveolar niche-resident cell types which drive IPF pathogenesis. Narrative We highlight how a wide array of cellular mechanisms that maintain cellular homeostasis become dysfunctional with ageing. Waning replicative capacity, genomic stability, mitochondrial function, proteostasis and metabolic function all contribute to a phenotype of vulnerability to ‘second hits’. We discuss how in IPF the alveolar epithelium becomes dysfunctional, highlighting changes in repair capacity and fundamental cellular phenotype and how interactions between abnormal epithelium and other alveolar niche-resident cell types perpetuate disease. Conclusions The ageing epithelium is a vulnerable epithelium which, with the cumulative effects of environmental exposures, fundamentally changes its behaviour towards stalled differentiation, failed repair and profibrotic signalling. Further dissection of aberrant epithelial behaviour, and its impact on other alveolar cell types, will allow identification of novel therapeutic targets aimed at earlier pathogenic events.

1 July 2026 in Physiology
Verified
Journal Article
Closed access
APAbida Islam Pranty
Abida Islam Pranty
SOSara Cuevas Ocaña
Sara Cuevas Ocaña
JDJennifer A. Dickens
Jennifer A. Dickens
Pulmonary surfactant is a lipoproteinaceous material secreted exclusively by alveolar type 2 cells into the alveolar space. It is primarily responsible for reducing the work of breathing by reducing surface tension at the air-liquid interface, though it has important additional roles in the innate immune response. Packaging of pulmonary surfactant is complex, involving specialized trafficking and posttranslational modification of both lipid and protein components to facilitate the formation of lamellar bodies in which surfactant is packaged before exocytosis. Aberrancies of pulmonary surfactant maturation, secretion, function, and recycling can have profound impacts on alveolar epithelial dysfunction and respiratory function. Manifestations are diverse, ranging from fatal neonatal respiratory failure to adult-onset interstitial lung disease. Here, we consider aspects of pulmonary surfactant genesis, function, and clearance in health and disease, also highlighting current and future therapies for surfactant-associated disease and the challenges of progressing research in the field.

30 August 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
KLKyungtae Lim
Kyungtae Lim
EREimear N. Rutherford
Eimear N. Rutherford
DSDawei Sun
Dawei Sun
DBDick J. H. Van Den Boomen
Dick J. H. Van Den Boomen
JEJames Edgar
James Edgar
JDJennifer A. Dickens
Jennifer A. Dickens
Alveolar type 2 (AT2) cells maintain lung health by acting as stem cells and producing pulmonary surfactant 1–3 . AT2 dysfunction underlies many lung diseases including interstitial lung disease (ILD), in which some inherited forms result from mislocalisation of surfactant protein C (SFTPC) variants 4,5 . Disease modelling and dissection of mechanisms remains challenging due to complexities in deriving and maintaining AT2 cells ex vivo. Here, we describe the development of expandable adult AT2-like organoids derived from human fetal lung which are phenotypically stable, can differentiate into AT1-like cells and are genetically manipulable. We use these organoids to test key effectors of SFTPC maturation identified in a forward genetic screen including the E3 ligase ITCH, demonstrating that their depletion phenocopies the pathological SFTPC redistribution seen for the SFTPC-I73T variant. In summary, we demonstrate the development of a novel alveolar organoid model and use it to identify effectors of SFTPC maturation necessary for AT2 health.